1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Deals

GSK Divests ThermaCare To Angelini

 
• By Tom Gallen

Italy's Angelini expects its acquisition of the ThermaCare pain-relief line to spur the company's European growth ambitions in the consumer healthcare market.

Coins
• Source: Shutterstock

Italy’s Angelini Pharma has acquired the rights to GlaxoSmithKline PLC’s ThermaCare pain-relief brand in all markets outside North America. According to local media reports, the purchase price was around €190m ($216m).

Under the terms of the deal, privately-held Angelini has gained the intellectual property rights relating to the ThermaCare products and brand, products under development and a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Australia’s Wellnex Life Poised To Enter UK’s CHC Market

 
• By Tom Gallen

Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.

That Loud Noise Echoing In US OTC Hearing Aid Market? Merger Of Eargo And HearX

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

More from Business

Reckitt Leans On Intimate Wellness Brands As OTC Stumbles

 
• By Tom Gallen

Gains for its Intimate Wellness portfolio - including a strong showing from Durex - helped offset lower sales of Reckitt's OTC cold & flu remedies in Q1. CEO Kris Licht shared his thoughts on the impact of US tariffs on the business and planned future divestments.

US Consumer Health Market People News: CHPA Foundation Contest, Celsius And AdvoCare Hires

 
• By Malcolm Spicer

CHPA Health In Hand Foundation accepting nominations for 2025 US Self-Care Marketing Awards; Celsius hires former PepsiCo as president/COO and closes $1.8bn acquisition of energy drink competitor Alani; and AdvoCare adds John Peirano as integrated marketing VP after hiring Kathy Blosser supply chain VP.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”